biostudies-otherGattelli A1335-1350https://www.ebi.ac.uk/biostudies/studies/S-ECPF-GEOD-41405EurocanPlatformEndocrine therapy is the main therapeutic option for patients with estrogen receptor alpha positive (ER+) breast cancer. Nevertheless, most of them become estrogen-independent and relapse after the treatment. Ret is a tyrosine kinase receptor that shows elevated expression levels in ER+ human breast tumors. In this study, we demonstrate that activation of the Ret receptor promotes proliferation as well as cell migration irrespective of endocrine therapy. Microarray data show that Ret activation involves changes in the expression of inflammatory- and motility-related genes. In vivo treatment with a Ret pathway inhibitor in a ER+/Ret+ mouse mammary cancer model, reduces tumor growth and lung metastasis even after endocrine therapy. Additionally, we show a connection between Ret and inflammatbiostudies-othertranscription profiling by arrayEurocanPlatformUnknown5EMBO molecular medicineHomo sapiensLienhard SKenner LTorres-Arzayus MIHynes NEBoulay ANalvarte ISchreiber MCarragher NSchlederer MGattelli ARoloff TCMacleod KKfalseGenes affected by Ret activation during estrogen stimulation or inhibition in MCF7/Aro cellsEndocrine therapy is the main therapeutic option for patients with estrogen receptor alpha positive (ER+) breast cancer. Nevertheless, most of them become estrogen-independent and relapse after the treatment. Ret is a tyrosine kinase receptor that shows elevated expression levels in ER+ human breast tumors. In this study, we demonstrate that activation of the Ret receptor promotes proliferation as well as cell migration irrespective of endocrine therapy. Microarray data show that Ret activation involves changes in the expression of inflammatory- and motility-related genes. In vivo treatment with a Ret pathway inhibitor in a ER+/Ret+ mouse mammary cancer model, reduces tumor growth and lung metastasis even after endocrine therapy. Additionally, we show a connection between Ret and inflammat2016-04-14T14:16:25Z2013 Sep2016-04-14T14:16:25Z2016-04-14T14:16:25ZS-ECPF-GEOD-41405GSE41405E-GEOD-41405EFO_0000305EFO_0000322E-GEOD-41405